Abbmira Therapeutics AG is a Swiss biotech startup fine-tuning the native immune system for improved outcomes in cancer therapy and autoimmune diseases.
At abbmira therapeutics AG, we are dedicated to revolutionizing the field of biomedicine through innovative, proprietary small molecule therapies that fine-tune the immune system to fight disease. Our team specializes in cutting-edge research and preclinical development aimed at addressing unmet medical needs, particularly in the area of immunomodulatory targeted therapies against cancer. We collaborate with industry partners, academics and stakeholders to accelerate drug discovery and bring forth advancements that can improve patient outcomes. Together, we strive to make a meaningful impact in the world of healthcare and drive progress within the pharmaceutical landscape.
Dr. Marc Creus is a biochemist with broad interests, particularly in science-innovation & tech-transfer both in academia and industry. He has also been involved in several startups and is currently founding CEO of the biotech Abbmira Therapeutics AG. Marc holds a PhD from Cambridge University.